No Data
Passage Bio to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced
Analysts' Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)
Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)
Express News | Canaccord Genuity Reiterates Buy on Passage Bio, Maintains $14 Price Target
Passage Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/05/2024 723.53% Canaccord Genuity → $14 Reiterates Buy → Buy 11/14/2023 194.12% Raymond James $9 → $5 M
New Innovation / R&D Risk for Passage Bio, Inc. – What's the Latest?
Kevin Matte : seem next level around 1.6 or so ^^